|

Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository

RECRUITINGPhase 1/2Sponsored by Brigham and Women's Hospital
Actively Recruiting
PhasePhase 1/2
SponsorBrigham and Women's Hospital
Started2025-06-17
Est. completion2027-08-31
Eligibility
Healthy vol.Accepted
Locations2 sites

Summary

Immunotherapies have improved cancer outcomes, but have a unique profile of immune-related adverse events (irAEs). Biorepositories have been established to collect data and samples to help improve our understanding of irAEs, however identifying patients who are eligible for these biorepositories in a timely fashion can be challenging. The goal of this study is to determine if an informatics system for automated irAE detection can improve registration to a prospective irAE biorepository (NCT04242095). The informatics system automatically "reads" participants' electronic health records (EHRs) and determines whether that patient may be experiencing an irAE. The main questions it aims to answer are: * Is it feasible to implement an informatics system for daily analysis of EHR data to detect irAEs? * Does the automated irAE detection system improve registration rates to an irAE biorepository at our institution following an eligible irAE? Researchers will compare standard irAE monitoring to informatics-assisted irAE monitoring to see if using the informatics system increases the registration rate and improves data entry efficiency and quality. Participants will: * Be randomly assigned to standard monitoring or informatics-assisted monitoring for irAE detection. * Have their EHR reviewed to collect demographic, medical, and cancer treatment history. * Be monitored for irAEs through daily automated analysis of their EHR data for up to 12 months or until registration in the biorepository.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Received or receiving a regimen containing one or more immuno-oncology therapeutics

Conditions3

CancerImmune-Related Adverse EventsMalignancy

Locations2 sites

Brigham and Women's Hospital
Boston, Massachusetts, 02115
Danielle Bitterman, MD617-732-6310dbitterman@bwh.harvard.edu
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
Elad Sharon, MD617-582-8900elad_sharon@dfci.harvard.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.